O-304, also written O304 and now developed as ATX-304, is an experimental pill that switches on AMPK, an enzyme your cells use to sense when they're low on energy. Exercise turns on the same enzyme, which is why O-304 gets called an exercise mimetic. It was discovered at Umeå University in Sweden and is being tested for type 2 diabetes and obesity.
It's not a peptide. O-304 is a small molecule, even though many research peptide sites sell it. Three small human studies have been reported (a phase 1 safety study, a 28-day phase 2a trial and a phase 1b study), and all were short.
- O-304 is an oral small molecule, not a peptide. ATX-304 is the same compound.
- It activates all forms of AMPK. Lab studies in muscle cells found it also uncouples mitochondria, so cells burn more fuel.
- In obese and diabetic mice, it improved blood sugar, insulin resistance and heart function.
- In a 28-day trial in 65 people with type 2 diabetes, it lowered fasting blood sugar in a subgroup and lowered blood pressure.
- In a 2026 study of 23 adults with obesity and prediabetes (about 15 on the drug), it raised resting energy use and cut liver and belly fat compared with their starting values.
- It's not FDA approved. WADA bans AMPK activators as a class.
| What it is | Small-molecule AMPK activator (C16H11Cl2N3O2S) |
| Molecular weight | About 380 g/mol |
| Other names | O304, ATX-304 |
| Developer | Betagenon, now part of Amplifier Therapeutics |
| Route | Oral |
| Doses in trials | 1,000 mg a day (28 days); 400 mg a day (8 to 16 weeks) |
| FDA status | Investigational; not approved |
| In sport | AMPK activators are prohibited (WADA S4) |
What Is O-304?
O-304 was discovered by Helena Edlund, Thomas Edlund and the late Olof Karlsson, working at Umeå University and the Swedish company Betagenon.[1][2] Betagenon is now owned by Amplifier Therapeutics, part of Cambrian Bio, which develops the compound as ATX-304. Betagenon remains the sponsor of its trials.[2]
It's an oral small molecule. Its structure isn't built from amino acids, so calling it a peptide is a mislabel.
ATX-304 vs OS-01
Some sellers list "OS-01" as another name for O-304.[10] That name already belongs to an unrelated product: OneSkin's OS-01, a 10-amino-acid skin care peptide that reduced markers of aging skin cells in lab-grown skin.[3][11] ATX-304 is a pill that activates AMPK. If you search for OS-01, you'll find both.
How O-304 Works
AMPK is an enzyme that turns on when a cell runs low on energy, such as during exercise or fasting. Once active, it pushes cells to take up glucose and burn fat.
O-304 keeps AMPK switched on by stopping the chemical tag that activates it from being removed. It works on every form of the enzyme, which is why it's called a pan-AMPK activator.[1] Later lab work in muscle cells found it also acts as a mitochondrial uncoupler: it makes mitochondria burn fuel less efficiently, which raises the cell's demand for glucose.[4]
What People Use O-304 For
- Blood sugar control. This is what it was developed for, as a type 2 diabetes treatment taken alongside metformin.
- Fat loss. Its developer now plans to test it as a weight loss drug that works differently from GLP-1 drugs.[5]
- Endurance and healthy aging. Biohackers use it as an exercise mimetic. The evidence for this is in aged mice.
The Research Behind O-304
Human studies
| Study | Who | Dose | What they found |
|---|---|---|---|
| TELLUS, phase 2a (2018)[1] | 65 adults with type 2 diabetes on metformin | 1,000 mg a day, 28 days | Lower fasting blood sugar in a subgroup; lower blood pressure; well tolerated |
| Phase 1b (2026)[5] | 23 adults with obesity and prediabetes | 400 mg a day, 8 weeks (optional extension to 16) | Higher adiponectin, less liver and visceral fat, resting energy use up to 33% higher than baseline; safe and well tolerated |
The 2018 diabetes trial was small and short. The authors call it an exploratory study. The blood sugar result comes from a post hoc analysis of the 49 patients whose starting blood sugar fell between 126 and 240 mg/dL, and the groups weren't well balanced at the start. In that group, fasting blood sugar fell by 0.60 mmol/L on O-304 versus 0.10 mmol/L on placebo. Blood pressure fell by 5.8/3.8 mmHg on O-304 and rose slightly on placebo.[1] The authors note the drop in blood sugar was modest compared with existing diabetes drugs.
The 2026 study reported changes from baseline. It was presented as a conference poster, not a full paper. Its results compare people with their own starting values rather than with the placebo group.[5]
Animal studies
| Study | Model | What they found |
|---|---|---|
| Steneberg, 2018[1] | Obese and diabetic mice | More glucose taken up by muscle, less insulin resistance, better heart pumping |
| Ericsson, 2021[6] | Aged mice | Reversed age-related insulin resistance; better heart function and running endurance |
| Zhu, 2022[7] | Naturally aging mice | Less kidney scarring and fewer aging cells in the kidney |
| Norlin, 2023[4] | Diabetic mice | Protected insulin-making beta cells and reversed diabetic heart muscle damage |
Is O-304 Legal?
O-304 is an investigational drug. It isn't FDA approved, and because it's under study as a drug, it can't legally be sold as a dietary supplement. It hasn't been nominated for, and isn't on, FDA's 503A bulk substance lists for compounding.[8] Sellers market it as a research chemical.
In sports, the WADA Prohibited List bans activators of AMPK as a class under section S4.4.1 (metabolic modulators), at all times.[9] O-304 isn't named, but it's an AMPK activator, so tested athletes should treat it as banned.
O-304 Dosage
No approved dose
O-304 is still in early trials, so there's no approved dose. The amounts below come from those trials and from sellers. Talk to a licensed clinician before you take it, especially if you use diabetes medicine.
O-304 dosage chart
| Source | Dose | How long |
|---|---|---|
| TELLUS diabetes trial[1] | 1,000 mg a day | 28 days |
| Phase 1b prediabetes study[5] | 400 mg once a day | 8 weeks, optional extension to 16 |
| Online users | 50 to 400 mg a day, often split morning and midday | Varies |
Capsules sold online commonly contain 100 or 150 mg.[10][12] Their contents aren't verified, so they may not match the trial drug. O-304 stays in the body a long time: in the diabetes trial, blood levels took about 14 days to level off.[1]
O-304 Side Effects
In the two trials with published results, O-304 was reported as well tolerated.[1][5] In the 2018 trial it caused no ECG abnormalities and no change in heart muscle mass.[1]
What isn't known:
- Long-term safety. The longest human exposure reported is 16 weeks.
- Low blood sugar with other drugs. O-304 lowers blood sugar, so combining it with insulin, sulfonylureas or GLP-1 drugs could add to their effect. This hasn't been studied.
- Product quality. Online capsules aren't made to drug standards, and the frequent mislabeling as a peptide or as OS-01 is a warning sign.
Who should avoid it: anyone pregnant or breastfeeding, anyone under 18, anyone on diabetes medicine without a doctor's supervision and athletes who are drug tested.
For more, see our posts on O-304 results and O-304 cost.
Frequently Asked Questions
What is O-304? An experimental pill that activates AMPK, the enzyme exercise switches on. It's being developed for diabetes and obesity.
Is O-304 a peptide? No. It's a small molecule with no amino acids.
Is ATX-304 the same as O-304? Yes. ATX-304 is the name its current developer, Amplifier Therapeutics, uses.
Is ATX-304 the same as OS-01? Not really. Some sellers use the name, but OS-01 is also an unrelated skin care peptide from OneSkin.
Does O-304 work? Early human studies show modest effects on blood sugar, blood pressure and liver fat. There are no large trials yet.
Does O-304 cause weight loss? In obese mice, yes. In people, it hasn't been shown.
What is the O-304 dose? Trials used 1,000 mg a day for 28 days and 400 mg a day for up to 16 weeks.
What are the side effects of O-304? It was well tolerated in short trials. Long-term effects are unknown.
Is O-304 legal? It's an investigational drug, not FDA approved and not a legal supplement.
Is O-304 banned by WADA? WADA bans AMPK activators as a class, so athletes should treat it as banned.
References
- Steneberg P, Lindahl E, Dahl U, et al. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight. 2018;3(12):e99114. PMID: 29925691
- Amplifier Therapeutics. Amplifier Therapeutics doses first patients in Phase 1B clinical trial. October 17, 2023. amplifier-tx.com
- Zonari A, Brace LE, Al-Katib K, et al. Senotherapeutic peptide treatment reduces biological age and senescence burden in human skin models. NPJ Aging. 2023;9(1):10. PMID: 37217561
- Norlin S, Axelsson J, Ericsson M, Edlund H. O304 ameliorates hyperglycemia in mice by dually promoting muscle glucose effectiveness and preserving β-cell function. Commun Biol. 2023;6(1):877. PMID: 37626210
- Thieroff-Ekerdt RI, Jacobs D, Hall J, et al. Phase 1b study of AMPK/mitochondrial activator ATX-304 in prediabetic obese participants. Diabetes. 2026;75(Suppl 1):1782-P. diabetesjournals.org
- Ericsson M, Steneberg P, Nyrén R, Edlund H. AMPK activator O304 improves metabolic and cardiac function, and exercise capacity in aged mice. Commun Biol. 2021;4(1):1306. PMID: 34795407
- Zhu M, Shen W, Li J, et al. AMPK activator O304 protects against kidney aging through promoting energy metabolism and autophagy. Front Pharmacol. 2022;13:836496. PMID: 35308246
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. fda.gov
- World Anti-Doping Agency. The 2026 Prohibited List, section S4.4.1. wada-ama.org
- Umbrella Labs. O-304 (ATX-304) capsules, product listing. umbrellalabs.is
- OneSkin. OS-01 FACE moisturizer ingredient list (Decapeptide-52, the OS-01 peptide). oneskin.co
- Peptide Regenesis. AMPK O-304 (ATX-304, OS-01) 150 mg, product listing. peptideregenesis.com
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any peptide therapy. Regulatory status may change.



